| 1. |
Duvaldestin P, Mahu J-L, Berthelot P. Effect of fasting on substrate specificity of rat liver UDP-glucuronosyltransferase.
Biochim Biophys Acta 1975;384:81–86.
|
| |
| 2. |
Abernethy DR, Greenblatt DJ, Divoll M, Shader RI. Enhanced glucuronide conjugation of drugs in obesity: studies of lorazepam,
oxazepam, and acetaminophen. J Lab Clin Med 1983;101:873–880.
|
| |
| 3. |
Hong JY, Pan JM, Gonzalez FJ, Gelboin HV, Yang CS. The induction of a specific form of cytochrome P-450 (P-450j) by fasting.
Biochem Biophys Res Commun 1987;142:1077–1083.
|
| |
| 4. |
Bellward GD, Chang T, Rodrigues B, et al. Hepatic cytochrome P-450j induction in the spontaneously diabetic BB rat. Mol Pharmacol
1988;33:140–143.
|
| |
| 5. |
Thomas H, Schladt L, Knehr M, Oesch F. Effect of diabetes and starvation on the activity of rat liver epoxide hydrolases,
glutathione S-transferases and peroxisomal beta-oxidation. Biochem Pharmacol 1989;38:4291–4297.
|
| |
| 6. |
Yamazoe Y, Murayama N, Shimada M, Yamauchi K, Kato R. Cytochrome P450 in livers of diabetic rats: regulation by growth hormone
and insulin. Arch Biochem Biophys 1989;268:567–575.
|
| |
| 7. |
Barnett CR, Gibson GG, Wolf CR, Flatt PR, Ioannides C. Induction of cytochrome P450III and P450IV family proteins in streptozotocin-induced
diabetes. Biochem J 1990;268:765–769.
|
| |
| 8. |
Song BJ, Veech RL, Saenger P. Cytochrome P450IIE1 is elevated in lymphocytes from poorly controlled insulin-dependent diabetics.
J Clin Endocrinol Metab 1990; 71:1036–1040.
|
| |
| 9. |
Donahue BS, Skottner-Lundin A, Morgan ET. Growth hormone-dependent and-independent regulation of cytochrome P-450 isozyme
expression in streptozotocin-diabetic rats. Endocrinology 1991;128:2065–2076.
|
| |
| 10. |
Chaudhary IP, Tuntaterdtum S, McNamara PJ, Robertson LW, Blouin RA. Effect of genetic obesity and phenobarbital treatment
on the hepatic conjugation pathways. J Pharmacol Exp Ther 1993;265:1333–1338.
|
| |
| 11. |
Ronis MJ, Huang J, Crouch J, et al. Cytochrome P450 CYP 2E1 induction during chronic alcohol exposure occurs by a two-step
mechanism associated with blood alcohol concentrations in rats. J Pharmacol Exp Ther 1993;264:944–950.
|
| |
| 12. |
Shimojo N, Ishizaki T, Imaoka S, Funae Y, Fujii S, Okuda K. Changes in amounts of cytochrome P450 isozymes and levels of catalytic
activities in hepatic and renal microsomes of rats with streptozocin-induced diabetes. Biochem Pharmacol 1993; 46:621–627.
|
| |
| 13. |
Van de Wiel JA, Fijneman PH, Teeuw KB, Van Ommen B, Noordhoek J, Bos RP. Influence of long-term ethanol treatment on rat liver
biotransformation enzymes. Alcohol 1993;10:397–402.
|
| |
| 14. |
Runge-Morris M, Vento C. Effects of streptozotocin-induced diabetes on rat liver sulfotransferase gene expression. Drug Metab
Dispos 1995;23:455–459.
|
| |
| 15. |
Visser TJ, van Haasteren GA, Linkels E, Kaptein E, van Toor H, de Greef WJ. Gender-specific changes in thyroid hormone-glucuronidating
enzymes in rat liver during short-term fasting and long-term food restriction. Eur J Endocrinol 1996; 135:489–497.
|
| |
| 16. |
Braun L, Coffey MJ, Puskas F, et al. Molecular basis of bilirubin UDP-glucuronosyltransferase induction in spontaneously diabetic
rats, acetone-treated rats and starved rats. Biochem J 1998;336:587–592.
|
| |
| 17. |
Kardon T, Coffey MJ, Banhegyi G, et al. Transcriptional induction of bilirubin UDP-glucuronosyltransrase by ethanol in rat
liver. Alcohol 2000;21:251–257.
|
| |
| 18. |
Agius C, Gidari AS. Effect of streptozotocin on the glutathione S-transferases of mouse liver cytosol. Biochem Pharmacol 1985;34:811–819.
|
| |
| 19. |
Grant MH, Duthie SJ. Conjugation reactions in hepatocytes isolated from streptozotocin-induced diabetic rats. Biochem Pharmacol
1987;36:3647–3655.
|
| |
| 20. |
Mukherjee B, Mukherjee JR, Chatterjee M. Lipid peroxidation, glutathione levels and changes in glutathione-related enzyme
activities in streptozotocin-induced diabetic rats. Immunol Cell Biol 1994;72:109–114.
|
| |
| 21. |
Raza H, Ahmed I, Lakhani MS, Sharma AK, Pallot D, Montague W. Effect of bitter melon (Momordica charantia) fruit juice on
the hepatic cytochrome P450-dependent monooxygenases and glutathione S-transferases in streptozotocin-induced diabetic rats. Biochem Pharmacol 1996;52:1639–1642.
|
| |
| 22. |
Wasserman WW, Fahl WE. Functional antioxidant responsive elements. Proc Natl Acad Sci USA 1997;94:5361–5366.
|
| |
| 23. |
Kang KW, Cho MK, Lee CH, Kim SG. Activation of phosphatidylinositol 3-kinase and Akt by tert-butylhydroquinone is responsible
for antioxidant response element-mediated rGSTA2 induction in H4IIE cells. Mol Pharmacol 2001;59:1147–1156.
|
| |
| 24. |
Dong ZG, Hong JY, Ma QA, et al. Mechanism of induction of cytochrome P-450ac (P-450j) in chemically induced and spontaneously
diabetic rats. Arch Biochem Biophys 1988;263:29–35.
|
| |
| 25. |
Favreau LV, Schenkman JB. Composition changes in hepatic microsomal cytochrome P-450 during onset of streptozocin-induced
diabetes and during insulin treatment. Diabetes 1988;37:577–584.
|
| |
| 26. |
Yamazoe Y, Murayama N, Shimada M, Imaoka S, Funae Y, Kato R. Suppression of hepatic levels of an ethanol-inducible P-450DM/j
by growth hormone: relationship between the increased level of P-450DM/j and depletion of growth hormone in diabetes. Mol
Pharmacol 1989;36:716–722.
|
| |
| 27. |
Donahue BS, Morgan ET. Effects of vanadate on hepatic cytochrome P-450 expression in streptozotocin-diabetic rats. Drug Metab
Dispos 1990;18:519–526.
|
| |
| 28. |
Thummel KE, Schenkman JB. Effects of testosterone and growth hormone treatment on hepatic microsomal P450 expression in the
diabetic rat. Mol Pharmacol 1990;37:119–129.
|
| |
| 29. |
Tunon MJ, Gonzalez P, Garcia-Pardo LA, Gonzalez J. Hepatic transport of bilirubin in rats with streptozotocin-induced diabetes.
J Hepatol 1991;13:71–77.
|
| |
| 30. |
Constantopoulos A, Matsaniotis N. Augmentation of uridine diphosphate glucuronyltransferase activity in rat liver by adenosine
3′,5′-monophosphate. Gastroenterology 1978;75:486–491.
|
| |
| 31. |
Ricci GL, Fevery J. Treatment of rats with glucagon, vasointestinal peptide or secretin has a different effect on bilirubin
and p-nitrophenol UDP-glucuronyl-transferase. Biochem Pharmacol 1988;37:3526–3528.
|
| |
| 32. |
Carrillo MC, Monti JA, Favre C, Carnovale CE. Acute regulation of hepatic glutathione S-transferase by insulin and glucagon. Toxicol Lett 1995;76:105–111.
|
| |
| 33. |
Kim SK, Woodcroft KJ, Novak RF. Insulin and glucagon regulation of glutathione S-transferase expression in primary cultured rat hepatocytes. J Pharmacol Exp Ther 2003;305:353–361.
|
| |
| 34. |
De Waziers I, Garlatti M, Bouguet J, Beaune PH, Barouki R. Insulin down-regulates cytochrome P450 2B and 2E expression at
the post-transcriptional level in the rat hepatoma cell line. Mol Pharmacol 1995;47:474–479.
|
| |
| 35. |
Woodcroft KJ, Novak RF. Insulin effects on CYP2E1, 2B, 3A, and 4A expression in primary cultured rat hepatocytes. Chem Biol
Interact 1997;107:75–91.
|
| |
| 36. |
Woodcroft KJ, Novak RF. Insulin differentially affects xenobiotic-enhanced, cytochrome P-450 (CYP)2E1, CYP2B, CYP3A, and CYP4A
expression in primary cultured rat hepatocytes. J Pharmacol Exp Ther 1999;289:1121–1127.
|
| |
| 37. |
Woodcroft KJ, Novak RF. The role of phosphatidylinositol 3-kinase, Src kinase, and protein kinase A signaling pathways in
insulin and glucagon regulation of CYP2E1 expression. Biochem Biophys Res Commun 1999;266:304–307.
|
| |
| 38. |
Iber H, Li-Masters T, Chen Q, Yu S, Morgan ET. Regulation of hepatic cytochrome P450 2C11 via cAMP: implications for down-regulation
in diabetes, fasting, and inflammation. J Pharmacol Exp Ther 2001;297:174–180.
|
| |
| 39. |
Viitala P, Posti K, Lindfors A, Pelkonen O, Raunio H. cAMP mediated upregulation of CYP2A5 in mouse hepatocytes. Biochem Biophys
Res Commun 2001;280: 761–767.
|
| |
| 40. |
Kim SK, Woodcroft KJ, Kim SG, Novak RF. Insulin and glucagon signaling in regulation of microsomal epoxide hydrolase expression
in primary cultured rat hepatocytes. Drug Metab Dispos 2003;31:1260–1268.
|
| |
| 41. |
Iber H, Morgan ET. Regulation of hepatic cytochrome P450 2C11 by transforming growth factor-beta, hepatocyte growth factor,
and interleukin-11. Drug Metab Dispos 1998;26:1042–1044.
|
| |
| 42. |
Donato MT, Gomez-Lechon MJ, Jover R, Nakamura T, Castell JV. Human hepatocyte growth factor down-regulates the expression
of cytochrome P450 isozymes in human hepatocytes in primary culture. J Pharmacol Exp Ther 1998;284:760–767.
|
| |
| 43. |
Ching KZ, Tenney KA, Chen J, Morgan ET. Suppression of constitutive cytochrome P450 gene expression by epidermal growth factor
receptor ligands in cultured rat hepatocytes. Drug Metab Dispos 1996;24:542–546.
|
| |
| 44. |
De Smet K, Loyer P, Gilot D, Vercruysse A, Rogiers V, Guguen-Guillouzo C. Effects of epidermal growth factor on CYP inducibility
by xenobiotics, DNA replication, and caspase activations in collagen I gel sandwich cultures of rat hepatocytes. Biochem Pharmacol
2001;61:1293–1303.
|
| |
| 45. |
Garcia MC, Thangavel C, Shapiro BH. Epidermal growth factor regulation of female-dependent CYP2A1 and CYP2C12 in primary rat
hepatocyte culture. Drug Metab Dispos 2001;29:111–120.
|
| |
| 46. |
Matsumoto M, Imagawa M, Aoki Y. Epidermal growth factor regulation of glutathione S-transferase gene expression in the rat is mediated by class Pi glutathione S-transferase enhancer I. Biochem J 2000;349:225–230.
|
| |
| 47. |
Desmots F, Rissel M, Gilot D, et al. Pro-inflammatory cytokines tumor necrosis factor α and interleukin-6 and survival factor
epidermal growth factor positively regulate the murine GSTA4 enzyme in hepatocytes. J Biol Chem 2002;277: 17892–17900.
|
| |
| 48. |
Woodcroft KJ, Hafner MS, Novak RF. Insulin signaling in the transcriptional and posttranscriptional regulation of CYP2E1 expression.
Hepatology 2002;35: 263–273.
|
| |
| 49. |
Perz M, Torlinska T. Insulin receptor—structural and functional characteristics. Med Sci Monit 2001;7:169–177.
|
| |
| 50. |
Sparrow LG, McKern NM, Gorman JJ, et al. The disulfide bonds in the C-terminal domains of the human insulin receptor ectodomain.
J Biol Chem 1997;272: 29460–29467.
|
| |
| 51. |
Cheatham B, Kahn CR. Cysteine 647 in the insulin receptor is required for normal covalent interaction between α-and β-subunits
and signal transduction. J Biol Chem 1992;267:7108–7115.
|
| |
| 52. |
Kahn CR. Banting Lecture. Insulin action, diabetogenes, and the cause of type II diabetes. Diabetes 1994;43:1066–1084.
|
| |
| 53. |
White MF, Kahn CR. The insulin signaling system. J Biol Chem 1994;269:1–4.
|
| |
| 54. |
White MF. IRS proteins and the common path to diabetes. Am J Physiol 2002; 283:E413–E422.
|
| |
| 55. |
Kao AW, Waters SB, Okada S, Pessin JE. Insulin stimulates the phosphorylation of the 66-and 52-kilodalton Shc isoforms by
distinct pathways. Endocrinology 1997; 138:2474–2480.
|
| |
| 56. |
Sasaoka T, Kobayashi M. The functional significance of Shc in insulin signaling as a substrate of the insulin receptor. Endocr
J 2000;47:373–381.
|
| |
| 57. |
Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, Burgess AW. Epidermal growth factor receptor: mechanisms of activation
and signalling. Exp Cell Res 2003;284:31–53.
|
| |
| 58. |
Whiteley B, Glaser L. Epidermal growth factor (EGF) promotes phosphorylation at threonine-654 of the EGF receptor: possible
role of protein kinase C in homologous regulation of the EGF receptor. J Cell Biol 1986;103:1355–1362.
|
| |
| 59. |
Tice DA, Biscardi JS, Nickles AL, Parsons SJ. Mechanism of biological synergy between cellular Src and epidermal growth factor
receptor. Proc Natl Acad Sci USA 1999;96:1415–1420.
|
| |
| 60. |
Fruman DA, Meyers RE, Cantley LC. Phosphoinositide kinases. Annu Rev Biochem 1998;67:481–507.
|
| |
| 61. |
Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002;296:1655–1657.
|
| |
| 62. |
Shields JM, Pruitt K, McFall A, Shaub A, Der CJ. Understanding Ras: ‘it ain’t over’ til it’s over’. Trends Cell Biol 2000;10:147–154.
|
| |
| 63. |
Alessi DR, Deak M, Casamayor A, et al. 3-Phosphoinositide-dependent protein kinase-1 (PDK1): structural and functional homology
with the Drosophila DSTPK61 kinase. Curr Biol 1997;7:776–789.
|
| |
| 64. |
Le Good JA, Ziegler WH, Parekh DB, Alessi DR, Cohen P, Parker PJ. Protein kinase C isotypes controlled by phosphoinositide
3-kinase through the protein kinase PDK1. Science 1998;281:2042–2045.
|
| |
| 65. |
Vanhaesebroeck B, Alessi DR. The PI3K-PDK1 connection: more than just a road to PKB. Biochem J 2000;346:561–576.
|
| |
| 66. |
Chan TO, Rittenhouse SE, Tsichlis PN. AKT/PKB and other D3 phosphoinositide-regulated kinases: kinase activation by phosphoinositide-dependent
phosphorylation. Annu Rev Biochem 1999;68:965–1014.
|
| |
| 67. |
Alessi DR, Andjelkovic M, Caudwell B, et al. Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J 1996;15:6541–6551.
|
| |
| 68. |
Jefferies HB, Fumagalli S, Dennis PB, Reinhard C, Pearson RB, Thomas G. Rapamycin suppresses 5’TOP mRNA translation through
inhibition of p70s6k EMBO J 1997;16:3693–3704.
|
| |
| 69. |
Kawasome H, Papst P, Webb S, et al. Targeted disruption of p70(s6k) defines its role in protein synthesis and rapamycin sensitivity.
Proc Natl Acad Sci USA 1998; 95:5033–5038.
|
| |
| 70. |
Kohn AD, Takeuchi F, Roth RA. Akt, a pleckstrin homology domain containing kinase, is activated primarily by phosphorylation.
J Biol Chem 1996;271: 21920–21926.
|
| |
| 71. |
Conus NM, Hemmings BA, Pearson RB. Differential regulation by calcium reveals distinct signaling requirements for the activation
of Akt and p70S6k. J Biol Chem 1998;273:4776–4782.
|
| |
| 72. |
Dufner A, Andjelkovic M, Burgering BM, Hemmings BA, Thomas G. Protein kinase B localization and activation differentially
affect S6 kinase 1 activity and eukaryotic translation initiation factor 4E-binding protein 1 phosphorylation. Mol Cell Biol
1999;19:4525–4534.
|
| |
| 73. |
Farese RV. Insulin-sensitive phospholipid signaling systems and glucose transport. Update II. Exp Biol Med (Maywood) 2001;226:283–295.
|
| |
| 74. |
Standaert ML, Bandyopadhyay G, Perez L, et al. Insulin activates protein kinases C-zeta and C-lambda by an autophosphorylation-dependent
mechanism and stimulates their translocation to GLUT4 vesicles and other membrane fractions in rat adipocytes. J Biol Chem
1999;274:25308–25316.
|
| |
| 75. |
Standaert ML, Bandyopadhyay G, Kanoh Y, Sajan MP, Farese RV. Insulin and PIP3 activate PKC-zeta by mechanisms that are both
dependent and independent of phosphorylation of activation loop (T410) and autophosphorylation (T560) sites. Biochemistry
2001;40:249–255.
|
| |
| 76. |
Mendez R, Kollmorgen G, White MF, Rhoads RE. Requirement of protein kinase C zeta for stimulation of protein synthesis by
insulin. Mol Cell Biol 1997;17: 5184–5192.
|
| |
| 77. |
Romanelli A, Martin KA, Toker A, Blenis J. p70 S6 kinase is regulated by protein kinase Czeta and participates in a phosphoinositide
3-kinase-regulated signalling complex. Mol Cell Biol 1999;19:2921–2928.
|
| |
| 78. |
Khosravi-Far R, Campbell S, Rossman KL, Der CJ. Increasing complexity of Ras signal transduction: involvement of Rho family
proteins. Adv Cancer Res 1998;72: 57–107.
|
| |
| 79. |
Chong H, Vikis HG, Guan KL. Mechanisms of regulating the Raf kinase family. Cell Signal 2003;15:463–469.
|
| |
| 80. |
Tzivion G, Luo Z, Avruch J. A dimeric 14-3-3 protein is an essential cofactor for Raf kinase activity. Nature 1998;394:88–92.
|
| |
| 81. |
Kubicek M, Pacher M, Abraham D, Podar K, Eulitz M, Baccarini M. Dephos-phorylation of Ser-259 regulates Raf-1 membrane association.
J Biol Chem 2002; 277:7913–7919.
|
| |
| 82. |
Light Y, Paterson H, Marais R. 14-3-3 antagonizes Ras-mediated Raf-1 recruitment to the plasma membrane to maintain signaling
fidelity. Mol Cell Biol 2002;22:4984–4996.
|
| |
| 83. |
Mason CS, Springer CJ, Cooper RG, Superti-Furga G, Marshall CJ, Marais R. Serine and tyrosine phosphorylations cooperate in
Raf-1, but not B-Raf activation. EMBO J 1999;18:2137–2148.
|
| |
| 84. |
Catling AD, Schaeffer HJ, Reuter CW, Reddy GR, Weber MJ. A proline-rich sequence unique to MEK1 and MEK2 is required for raf
binding and regulates MEK function. Mol Cell Biol 1995;15:5214–5225.
|
| |
| 85. |
Lewis TS, Shapiro PS, Ahn NG. Signal transduction through MAP kinase cascades. Adv Cancer Res 1998;74:49–139.
|
| |
| 86. |
Kyriakis JM, Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation.
Physiol Rev 2001;81: 807–869.
|
| |
| 87. |
Hagemann C, Blank JL. The ups and downs of MEK kinase interactions. Cell Signal 2001;13:863–875.
|
| |
| 88. |
Duckworth BC, Cantley LC. Conditional inhibition of the mitogen-activated protein kinase cascade by wortmannin. Dependence
on signal strength. J Biol Chem 1997;272:27665–27670.
|
| |
| 89. |
Bisotto S, Fixman ED. Src-family tyrosine kinases, phosphoinositide 3-kinase and Gab1 regulate extracellular signal-regulated
kinase 1 activation induced by the type A endothelin-1 G-protein-coupled receptor. Biochem J 2001;360:77–85.
|
| |
| 90. |
Yu CF, Roshan B, Liu ZX, Cantley LG. ERK regulates the hepatocyte growth factor-mediated interaction of Gab1 and the phosphatidylinositol
3-kinase. J Biol Chem 2001;276:32552–3558.
|
| |
| 91. |
Yu CF, Liu ZX, Cantley LG. ERK negatively regulates the epidermal growth factor-mediated interaction of Gab1 and the phosphatidylinositol
3-kinase. J Biol Chem 2002;277:19382–19388.
|
| |
| 92. |
Moelling K, Schad K, Bosse M, Zimmermann S, Schweneker M. Regulation of Raf-Akt Cross-talk. J Biol Chem 2002;277:31099–31106.
|
| |
| 93. |
Park HS, Kim MS, Huh SH, et al. Akt (protein kinase B) negatively regulates SEK1 by means of protein phosphorylation. J Biol
Chem 2002;277:2573–2578.
|
| |
| 94. |
Fujishiro M, Gotoh Y, Katagiri H, et al. Three mitogen-activated protein kinases inhibit insulin signaling by different mechanisms
in 3T3-L1 adipocytes. Mol Endocrinol 2003;17:487–497.
|
| |
| 95. |
Kim JW, Lee JE, Kim MJ, Cho EG, Cho SG, Choi EJ. Glycogen synthase kinase 3 beta is a natural activator of mitogen-activated
protein kinase/extracellular signal-regulated kinase kinase kinase 1 (MEKK1). J Biol Chem 2003;278:13995–14001.
|
| |
| 96. |
Lee YH, Giraud J, Davis RJ, White MF. c-Jun N-terminal kinase (JNK) mediates feedback inhibition of the insulin signaling
cascade. J Biol Chem 2003;278: 2896–2902.
|
| |
| 97. |
Yamamoto-Honda R, Tobe K, Kaburagi Y, et al. Upstream mechanisms of glycogen synthase activation by insulin and insulin-like
growth factor-I. Glycogen synthase activation is antagonized by wortmannin or LY294002 but not by rapamycin or by inhibiting
p21ras. J Biol Chem 1995;270:2729–2734.
|
| |
| 98. |
Nakamura K, Zhou CJ, Parente J, Chew CS. Parietal cell MAP kinases: multiple activation pathways. Am J Physiol 1996;271:G640–G649.
|
| |
| 99. |
Scheid MP, Duronio V. Phosphatidylinositol 3-OH kinase activity is not required for activation of mitogen-activated protein
kinase by cytokines. J Biol Chem 1996; 271:18134–18139.
|
| |
| 100. |
Cross DA, Alessi DR, Vandenheede JR, McDowell HE, Hundal HS, Cohen P. The inhibition of glycogen synthase kinase-3 by insulin
or insulin-like growth factor 1 in the rat skeletal muscle cell line L6 is blocked by wortmannin, but not by rapamycin: evidence
that wortmannin blocks activation of the mitogen-activated protein kinase pathway in L6 cells between Ras and Raf. Biochem
J 1994;303:21–26.
|
| |
| 101. |
Standaert ML, Bandyopadhyay G, Farese RV. Studies with wortmannin suggest a role for phosphatidylinositol 3-kinase in the
activation of glycogen synthase and mitogen-activated protein kinase by insulin in rat adipocytes: comparison of insulin and
protein kinase C modulators. Biochem Biophys Res Commun 1995; 209:1082–1088.
|
| |
| 102. |
Marra F, Pinzani M, DeFranco R, Laffi G, Gentilini P. Involvement of phosphatidylinositol 3-kinase in the activation of extracellular
signal-regulated kinase by PDGF in hepatic stellate cells. FEBS Lett 1995;376:141–145.
|
| |
| 103. |
Zimmermann S, Moelling K. Phosphorylation and regulation of Raf by Akt (protein kinase B). Science 1999;286:1741–1744.
|
| |
| 104. |
Rommel C, Clarke BA, Zimmermann S, et al. Differentiation stage-specific inhibition of the Raf-MEK-ERK pathway by Akt. Science
1999;286:1738–1741.
|
| |
| 105. |
Hirosumi J, Tuncman G, Chang L, et al. A central role for JNK in obesity and insulin resistance. Nature 2002;420:333–336.
|
| |
| 106. |
Zhang ZY, Zhou B, Xie L. Modulation of protein kinase signaling by protein phosphatases and inhibitors. Pharmacol Ther 2002;93:307–317.
|
| |
| 107. |
Asante-Appiah E, Kennedy BP. Protein tyrosine phosphatases: the quest for negative regulators of insulin action. Am J Physiol
2003;284:E663–E670.
|
| |
| 108. |
Wu C, Sun M, Liu L, Zhou GW. The function of the protein tyrosine phosphatase SHP-1 in cancer. Gene 2003;306:1–12.
|
| |
| 109. |
Elchebly M, Cheng A, Tremblay ML. Modulation of insulin signaling by protein tyrosine phosphatases. J Mol Med 2000;78:473–482.
|
| |
| 110. |
Tonks NK, Diltz CD, Fischer EH. Characterization of the major protein-tyrosine-phosphatases of human placenta. J Biol Chem
1988;263:6731–6737.
|
| |
| 111. |
Charbonneau H, Tonks NK, Kumar S, et al. Human placenta protein-tyrosine-phosphatase: amino acid sequence and relationship
to a family of receptor-like proteins. Proc Natl Acad Sci USA 1989;86:5252–5256.
|
| |
| 112. |
Frangioni JV, Oda A, Smith M, Salzman EW, Neel BG. Calpain-catalyzed cleavage and subcellular relocation of protein phosphotyrosine
phosphatase 1B (PTP-1B) in human platelets. EMBO J 1993;12:4843–4856.
|
| |
| 113. |
Elchebly M, Payette P, Michaliszyn E, et al. Increased insulin sensitivity and obesity resistance in mice lacking the protein
tyrosine phosphatase-1B gene. Science 1999;283:1544–1548.
|
| |
| 114. |
Salmeen A, Andersen JN, Myers MP, Tonks NK, Barford D. Molecular basis for the dephosphorylation of the activation segment
of the insulin receptor by protein tyrosine phosphatase 1B. Mol Cell 2000;6:1401–1412.
|
| |
| 115. |
Seely BL, Staubs PA, Reichart DR, et al. Protein tyrosine phosphatase 1B interacts with the activated insulin receptor. Diabetes
1996;45:1379–1385.
|
| |
| 116. |
Bandyopadhyay D, Kusari A, Kenner KA, et al. Protein-tyrosine phosphatase 1B complexes with the insulin receptor in vivo and
is tyrosine-phosphorylated in the presence of insulin. J Biol Chem 1997;272:1639–1645.
|
| |
| 117. |
Mahadev K, Zilbering A, Zhu L, Goldstein BJ. Insulin-stimulated hydrogen peroxide reversibly inhibits protein-tyrosine phosphatase
1b in vivo and enhances the early insulin action cascade. J Biol Chem 2001;276:21938–21942.
|
| |
| 118. |
Wu X, Hoffstedt J, Deeb W, et al. Depot-specific variation in protein-tyrosine phosphatase activities in human omental and
subcutaneous adipose tissue: a potential contribution to differential insulin sensitivity. J Clin Endocrinol Metab 2001; 86:5973–5980.
|
| |
| 119. |
Dadke S, Kusari A, Kusari J. Phosphorylation and activation of protein tyrosine phosphatase (PTP) 1B by insulin receptor.
Mol Cell Biochem 2001;221:147–154.
|
| |
| 120. |
Ravichandran LV, Chen H, Li Y, Quon MJ. Phosphorylation of PTP1B at Ser(50) by Akt impairs its ability to dephosphorylate
the insulin receptor. Mol Endocrinol 2001;15:1768–1780.
|
| |
| 121. |
Tao J, Malbon CC, Wang H Y. Insulin stimulates tyrosine phosphorylation and inactivation of protein-tyrosine phosphatase 1B
in vivo. J Biol Chem 2001;276: 29520–29525.
|
| |
| 122. |
Liu F, Chernoff J. Protein tyrosine phosphatase 1B interacts with and is tyrosine phosphorylated by the epidermal growth factor
receptor. Biochem J 1997;327: 139–145.
|
| |
| 123. |
Bjorge JD, Pang A, Fujita DJ. Identification of protein-tyrosine phosphatase 1B as the major tyrosine phosphatase activity
capable of dephosphorylating and activating c-Src in several human breast cancer cell lines. J Biol Chem 2000;275:41439–41446.
|
| |
| 124. |
Milarski KL, Saltiel AR. Expression of catalytically inactive Syp phosphatase in 3T3 cells blocks stimulation of mitogen-activated
protein kinase by insulin. J Biol Chem 1994;269:21239–21243.
|
| |
| 125. |
Bennett AM, Hausdorff SF, O’Reilly AM, Freeman RM, Neel BG. Multiple requirements for SHPTP2 in epidermal growth factor-mediated
cell cycle progression. Mol Cell Biol 1996;16:1189–1202.
|
| |
| 126. |
Chen H, Wertheimer SJ, Lin CH, et al. Protein-tyrosine phosphatases PTP1B and syp are modulators of insulin-stimulated translocation
of GLUT4 in transfected rat adipose cells. J Biol Chem 1997;272:8026–8031.
|
| |
| 127. |
Ouwens DM, van der Zon GC, Maassen JA. Modulation of insulin-stimulated glycogen synthesis by Src homology phosphatase 2.
Mol Cell Endocrinol 2001;175:131–140.
|
| |
| 128. |
Nichols A, Camps M, Gillieron C, et al. Substrate recognition domains within extracellular signal-regulated kinase mediate
binding and catalytic activation of mitogen-activated protein kinase phosphatase-3. J Biol Chem 2000;275: 24613–24621.
|
| |
| 129. |
Masuda K, Shima H, Watanabe M, Kikuchi K. MKP-7, a novel mitogen-activated protein kinase phosphatase, functions as a shuttle
protein. J Biol Chem 2001;276: 39002–39011.
|
| |
| 130. |
Camps M, Nichols A, Arkinstall S. Dual specificity phosphatases: a gene family for control of MAP kinase function. FASEB J
2000;14:6–16.
|
| |
| 131. |
Sim AT, Baldwin ML, Rostas JA, Holst J, Ludowyke RI. The role of serine/threonine protein phosphatases in exocytosis. Biochem
J 2003;373:641–659.
|
| |
| 132. |
Cohen P. The structure and regulation of protein phosphatases. Annu Rev Biochem 1989;58:453–508.
|
| |
| 133. |
Winder DG, Sweatt JD. Roles of serine/threonine phosphatases in hippocampal synaptic plasticity. Nat Rev Neurosci 2001;2:461–474.
|
| |
| 134. |
Klumpp S, Krieglstein J. Serine/threonine protein phosphatases in apoptosis. Curr Opin Pharmacol 2002;2:458–462.
|
| |
| 135. |
Brady MJ, Saltiel AR. The role of protein phosphatase-1 in insulin action. Recent Prog Horm Res 2001;56:157–173.
|
| |
| 136. |
Keyse SM. Protein phosphatases and the regulation of mitogen-activated protein kinase signalling. Curr Opin Cell Biol 2000;12:186–192.
|
| |
| 137. |
Birle D, Bottini N, Williams S, Huynh H, deBelle I, Adamson E, Mustelin T. Negative feedback regulation of the tumor suppressor
PTEN by phosphoinosi-tide-induced serine phosphorylation. J Immunol 2002;169:286–291.
|
| |
| 138. |
Ross AH, Baltimore D, Eisen HN. Phosphotyrosine-containing proteins isolated by affinity chromatography with antibodies to
a synthetic hapten. Nature 1981; 294:654–656.
|
| |
| 139. |
Fabbro D, Parkinson D, Matter A. Protein tyrosine kinase inhibitors: new treatment modalities? Curr Opin Pharmacol 2002;2:374–381.
|
| |
| 140. |
Toledo LM, Lydon NB, Elbaum D. The structure-based design of ATP-site directed protein kinase inhibitors. Curr Med Chem 1999;6:775–805.
|
| |
| 141. |
Alessi DR, Cuenda A, Cohen P, Dudley DT, Saltiel AR. PD 098059 is a specific inhibitor of the activation of mitogen-activated
protein kinase kinase in vitro and in vivo. J Biol Chem 1995;270:27489–27494.
|
| |
| 142. |
Favata MF, Horiuchi KY, Manos EJ, et al. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J
Biol Chem 1998;273:18623–18632.
|
| |
| 143. |
Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors.
Biochem J 2000;351:95–105.
|
| |
| 144. |
Karihaloo A, O’Rourke DA, Nickel C, Spokes K, Cantley LG. Differential MAPK pathways utilized for HGF-and EGF-dependent renal
epithelial morphogenesis. J Biol Chem 2001;276:9166–9173.
|
| |
| 145. |
Cuenda A, Rouse J, Doza YN, et al. SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular
stresses and interleukin-1. FEBS Lett 1995;364:229–233.
|
| |
| 146. |
Eyers PA, Craxton M, Morrice N, Cohen P, Goedert M. Conversion of SB 203580-insensitive MAP kinase family members to drug-sensitive
forms by a single amino-acid substitution. Chem Biol 1998;5:321–328.
|
| |
| 147. |
Lali FV, Hunt AE, Turner SJ, Foxwell BM. The pyridinyl imidazole inhibitor SB203580 blocks phosphoinositide-dependent protein
kinase activity, protein kinase B phosphorylation, and retinoblastoma hyperphosphorylation in inter-leukin-2-stimulated T
cells independently of p38 mitogen-activated protein kinase. J Biol Chem 2000;275:7395–7402.
|
| |
| 148. |
Wang L, Gout I, Proud CG. Cross-talk between the ERK and p70 S6 kinase (S6K) signaling pathways. MEK-dependent activation
of S6K2 in cardiomyocytes. J Biol Chem 2001;276:32670–32677.
|
| |
| 149. |
Frantz B, Klatt T, Pang M, et al. The activation state of p38 mitogen-activated protein kinase determines the efficiency of
ATP competition for pyridinylimidazole inhibitor binding. Biochemistry 1998;37:13846–13853.
|
| |
| 150. |
Bennett BL, Sasaki DT, Murray BW, et al. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad
Sci USA 2001;98: 13681–13686.
|
| |
| 151. |
Han Z, Boyle DL, Chang L, et al. c-Jun N-terminal kinase is required for metal-loproteinase expression and joint destruction
in inflammatory arthritis. J Clin Invest 2001;108:73–81.
|
| |
| 152. |
Bain J, McLauchlan H, Elliott M, Cohen P. The specificities of protein kinase inhibitors: an update. Biochem J 2003;371:199–204.
|
| |
| 153. |
Blake RA, Broome MA, Liu X, et al. SU6656, a selective src family kinase inhibitor, used to probe growth factor signaling.
Mol Cell Biol 2000;20:9018–9027.
|
| |
| 154. |
Hanke JH, Gardner JP, Dow RL, et al. Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study
of Lck-and FynT-dependent T cell activation. J Biol Chem 1996;271:695–701.
|
| |
| 155. |
Price DJ, Grove JR, Calvo V, Avruch J, Bierer BE. Rapamycin-induced inhibition of the 70-kilodalton S6 protein kinase. Science
1992;257:973–977.
|
| |
| 156. |
Kuo CJ, Chung J, Fiorentino DF, Flanagan WM, Blenis J, Crabtree GR. Rapamycin selectively inhibits interleukin-2 activation
of p70 S6 kinase. Nature 1992;358:70–73.
|
| |
| 157. |
Hidalgo M, Rowinsky EK. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene 2000;19:6680–6686.
|
| |
| 158. |
Toullec D, Pianetti P, Coste H, et al. The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase
C. J Biol Chem 1991;266: 15771–15781.
|
| |
| 159. |
Davis PD, Hill CH, Keech E, et al. Potent selective inhibitors of protein kinase C. FEBS Lett 1989;259:61–63.
|
| |
| 160. |
Gordge PC, Ryves WJ. Inhibitors of protein kinase C. Cell Signal 1994;6: 871–882.
|
| |
| 161. |
Martiny-Baron G, Kazanietz MG, Mischak H, et al. Selective inhibition of protein kinase C isozymes by the indolocarbazole
Go 6976. J Biol Chem 1993;268: 9194–9197.
|
| |
| 162. |
Vlahos CJ, Matter WF, Hui KY, Brown RF. A specific inhibitor of phosphatidyl-inositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 1994;269:5241–5248.
|
| |
| 163. |
Stein RC. Prospects for phosphoinositide 3-kinase inhibition as a cancer treatment. Endocr Relat Cancer 2001;8:237–248.
|
| |
| 164. |
Brunn GJ, Williams J, Sabers C, Wiederrecht G, Lawrence JC Jr, Abraham RT. Direct inhibition of the signaling functions of
the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002. EMBO J 1996;15:5256–5267.
|
| |
| 165. |
Izzard RA, Jackson SP, Smith GC. Competitive and noncompetitive inhibition of the DNA-dependent protein kinase. Cancer Res
1999;59:2581–2586.
|
| |
| 166. |
Wang D, Sul HS. Insulin stimulation of the fatty acid synthase promoter is mediated by the phosphatidylinositol 3-kinase pathway.
Involvement of protein kinase B/Akt. J Biol Chem 1998;273:25420–25426.
|
| |
| 167. |
Kitamura T, Ogawa W, Sakaue H, et al. Requirement for activation of the serine-threonine kinase Akt (protein kinase B) in
insulin stimulation of protein synthesis but not of glucose transport. Mol Cell Biol 1998;18:3708–3717.
|
| |
| 168. |
House C, Kemp BE. Protein kinase C contains a pseudosubstrate prototope in its regulatory domain. Science 1987;238:1726–1728.
|
| |
| 169. |
Yeh P, Perricaudet M. Advances in adenoviral vectors: from genetic engineering to their biology. FASEB J 1997;11:615–623.
|
| |
| 170. |
He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B. A simplified system for generating recombinant adenoviruses. Proc
Natl Acad Sci USA 1998;95:2509–2514.
|
| |
| 171. |
Becker TC, Noel RJ, Coats WS, et al. Use of recombinant adenovirus for metabolic engineering of mammalian cells. Methods Cell
Biol 1994;43:161–189.
|
| |
| 172. |
Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA
in Caenorhabditis elegans. Nature 1998;391:806–811.
|
| |
| 173. |
Hamilton AJ, Baulcombe DC. A species of small antisense RNA in posttran-scriptional gene silencing in plants. Science 1999;286:950–952.
|
| |
| 174. |
Zamore PD, Tuschl T, Sharp PA, Bartel DP. RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23
nucleotide intervals. Cell 2000; 101:25–33.
|
| |
| 175. |
Elbashir SM, Lendeckel W, Tuschl T. RNA interference is mediated by 21-and 22-nucleotide RNAs. Genes Dev 2001;15:188–200.
|
| |
| 176. |
McManus MT, Sharp PA. Gene silencing in mammals by small interfering RNAs. Nat Rev Genet 2002;3:737–747.
|
| |
| 177. |
Reinhart BJ, Slack FJ, Basson M, et al. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature 2000;403:901–906.
|
| |
| 178. |
Pasquinelli AE, Reinhart BJ, Slack F, et al. Conservation of the sequence and temporal expression of let-7 heterochronic regulatory
RNA. Nature 2000; 408:86–89.
|
| |
| 179. |
Grishok A, Pasquinelli AE, Conte D, et al. Genes and mechanisms related to RNA interference regulate expression of the small
temporal RNAs that control C. elegans developmental timing. Cell 2001;106:23–34.
|
| |
| 180. |
Dykxhoorn DM, Novina CD, Sharp PA. Killing the messenger: short RNAs that silence gene expression. Nat Rev Mol Cell Biol 2003;4:457–467.
|
| |
| 181. |
Baglioni C, Nilsen TW. Mechanisms of antiviral action of interferon. Interferon. 1983;5:23–42.
|
| |
| 182. |
Williams BR. Role of the double-stranded RNA-activated protein kinase (PKR) in cell regulation. Biochem Soc Trans 1997;25:509–513.
|
| |
| 183. |
Caplen NJ, Parrish S, Imani F, Fire A, Morgan RA. Specific inhibition of gene expression by small double-stranded RNAs in
invertebrate and vertebrate systems. Proc Natl Acad Sci USA 2001;98:9742–9747.
|
| |
| 184. |
Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference
in cultured mammalian cells. Nature 2001;411:494–498.
|
| |
| 185. |
McManus MT, Haines BB, Dillon CP, et al. Small interfering RNA-mediated gene silencing in T lymphocytes. J Immunol 2002;169:5754–5760.
|
| |
| 186. |
Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science
2002;296:550–553.
|
| |
| 187. |
Lee NS, Dohjima T, Bauer G, et al. Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells.
Nat Biotechnol 2002;20:500–555.
|
| |
| 188. |
Miyagishi M, Taira K. U6 promoter-driven siRNAs with four uridine 3′ overhangs efficiently suppress targeted gene expression
in mammalian cells. Nat Biotechnol 2002;20:497–500.
|
| |
| 189. |
Paul CP, Good PD, Winer I, Engelke DR. Effective expression of small interfering RNA in human cells. Nat Biotechnol 2002;20:505–508.
|
| |
| 190. |
Sui G, Soohoo C, Affarel B, et al. A DNA vector-based RNAi technology to suppress gene expression in mammalian cells. Proc
Natl Acad Sci USA 2002;99: 5515–5520.
|
| |
| 191. |
Yu JY, DeRuiter SL, Turner DL. RNA interference by expression of shortinterfering RNAs and hairpin RNAs in mammalian cells.
Proc Natl Acad Sci USA 2002;99:6047–6052.
|
| |
| 192. |
Paddison PJ, Caudy AA, Hannon GJ. Stable suppression of gene expression by RNAi in mammalian cells. Proc Natl Acad Sci USA
2002;99:1443–1448.
|
| |
| 193. |
Amarzguioui M, Holen T, Babaie E, Prydz H. Tolerance for mutations and chemical modifications in a siRNA. Nucl Acids Res 2003;31:589–595.
|
| |
| 194. |
McManus MT, Petersen CP, Haines BB, Chen J, Sharp PA. Gene silencing using micro-RNA designed hairpins. RNA 2002;8:842–850.
|
| |